Tozorakimab Met Primary Endpoint in Phase III MIRANDA Trial in Patients With COPD
April 21, 2026
April 21, 2026
WILMINGTON, Delaware, April 21 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
Third positive pivotal Phase III clinical trial of AstraZeneca's IL-33 targeting biologic further demonstrates its benefits in COPD
*
Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-cl . . .
* * *
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
Third positive pivotal Phase III clinical trial of AstraZeneca's IL-33 targeting biologic further demonstrates its benefits in COPD
*
Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-cl . . .